LD-2 disclosure · 3rd Quarter - Report
ALLERGAN USA, INC.
via ALLERGAN USA, INC.
Client
- Name
- ALLERGAN USA, INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- ALLERGAN USA, INC.
- Description
- Pharmaceutical development and manufacturing
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
8 issuesTrade (domestic/foreign)
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
LobbyistsBRENT J FISK · ROBERT W. LIVELY
TargetedSENATE · HOUSE OF REPRESENTATIVES · Patent & Trademark Office (PTO) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
LobbyistsBRENT J FISK · ROBERT W. LIVELY
TargetedSENATE · HOUSE OF REPRESENTATIVES · Patent & Trademark Office (PTO) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Budget/Appropriations
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).